Chronic Renal Failure

Nephrology
5
Pipeline Programs
5
Companies
16
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 5 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
1
lactate and bicarbonate buffered dialysis solutionsPhase 41 trial
Active Trials
NCT01632046Completed42Est. Mar 2007
Pfizer
PfizerNEW YORK, NY
3 programs
1
2
Epoetin HospiraPhase 31 trial
FragminPhase 31 trial
Epoetin HospiraPhase 11 trial
Active Trials
NCT01170078Completed107Est. Jan 2011
NCT01473420Completed320Est. Feb 2014
NCT01879618Completed152Est. Mar 2016
Takeda
TakedaTOKYO, Japan
1 program
1
peginesatidePhase 3Peptide5 trials
Active Trials
NCT01478971Completed184Est. Feb 2013
NCT00752791Completed59Est. May 2010
NCT00752609Completed102Est. Dec 2009
+2 more trials
Astellas
AstellasChina - Shenyang
1 program
bixalomerN/A2 trials
Active Trials
NCT02805348Completed144Est. Dec 2018
NCT01903213Completed123Est. Dec 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heidelberg Pharmalactate and bicarbonate buffered dialysis solutions
PfizerFragmin
PfizerEpoetin Hospira
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
Takedapeginesatide
PfizerEpoetin Hospira
Takedapeginesatide
Astellasbixalomer

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 3,980 patients across 16 trials

NCT01632046Heidelberg Pharmalactate and bicarbonate buffered dialysis solutions

Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children

Start: Mar 2004Est. completion: Mar 200742 patients
Phase 4Completed
NCT01879618PfizerFragmin

Use Of Fragmin In Hemodialysis

Start: Oct 2013Est. completion: Mar 2016152 patients
Phase 3Completed
NCT01473420PfizerEpoetin Hospira

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

Start: Jan 2012Est. completion: Feb 2014320 patients
Phase 3Completed
NCT01478971Takedapeginesatide

Conversion Study From Epoetin Alfa to Monthly Peginesatide Injection in Patients With Chronic Kidney Disease on Dialysis

Start: Oct 2011Est. completion: Feb 2013184 patients
Phase 3Completed
NCT00598442Takedapeginesatide

Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Start: Nov 2007Est. completion: Dec 2009493 patients
Phase 3Completed
NCT00597584Takedapeginesatide

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Start: Oct 2007Est. completion: Jan 2010823 patients
Phase 3Completed
NCT00598273Takedapeginesatide

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Start: Oct 2007Est. completion: Feb 2010490 patients
Phase 3Completed
NCT00597753Takedapeginesatide

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

Start: Sep 2007Est. completion: Jan 2010803 patients
Phase 3Completed
NCT00752791Takedapeginesatide

Efficacy and Safety of Peginesatide Injection for the Maintenance Treatment of Anemia in Peritoneal Dialysis Participants Previously Treated With Epoetin.

Start: Oct 2008Est. completion: May 201059 patients
Phase 2Completed
NCT00752609Takedapeginesatide

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Start: Sep 2008Est. completion: Dec 2009102 patients
Phase 2Completed
NCT00680043Takedapeginesatide

Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA

Start: Jun 2008Est. completion: Aug 2009114 patients
Phase 2Completed
NCT00314795Takedapeginesatide

Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease

Start: Apr 2006Est. completion: Oct 201622 patients
Phase 2Completed
NCT01170078PfizerEpoetin Hospira

A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment

Start: Jul 2010Est. completion: Jan 2011107 patients
Phase 1Completed
NCT00629876Takedapeginesatide

A Safety and Tolerability Study of Peginesatide in Anemic Cancer Patients Receiving Cytotoxic Chemotherapy.

Start: Jan 2008Est. completion: Jun 20082 patients
Phase 1Terminated
NCT02805348Astellasbixalomer

Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease

Start: Jun 2016Est. completion: Dec 2018144 patients
N/ACompleted
NCT01903213Astellasbixalomer

Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis

Start: Mar 2013Est. completion: Dec 2019123 patients
N/ACompleted

Related Jobs in Nephrology

Thesis work, 60 credits – Establishing In Vitro Models of Mitochondrial Dysfunction in Acute Kidney Injury for Preclinical Drug Discovery

AstraZeneca
Sweden - Gothenburg
6d ago

Director, Strategy & Operations-Nephrology Franchise

Biogen
Cambridge, MA
1w ago
$195K - $269K/yr

Associate Director – Nephrology Market Access Strategy

Biogen
Cambridge, MA
1w ago
$164K - $226K/yr

Vice President, Head of Renal Sales

Novartis
Field Non-Sales (USA)
1w ago
$274K - $510K/yr

Medical Science Liaison, CardioRenal - Portland, OR

AstraZeneca
Portland - OR, US
1w ago

Area Sales Manager (Florida Region)

Outset Medical
Florida Region
1w ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

Chronic Kidney Disease(86)Renal Impairment(67)End Stage Renal Disease(56)Kidney Transplantation(49)Renal Insufficiency(27)Chronic Kidney Diseases(25)Kidney Transplant(19)Diabetic Nephropathies(18)Kidney Diseases(17)Kidney Transplant Rejection(16)